Maintenance therapy with the FMS‐like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS‐like tyrosine kinase 3–internal tandem duplication acute myeloid leukemia: A phase 2 study

Documenti analoghi

• A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS‐like tyrosine kinase 3 (FLT3)‐mutated acute myeloid leukemia
  di: Alexandre Bazinet, et al.
  Pubblicazione: (2025)
• Allogeneic transplantation provides added benefit to FMS‐like tyrosine kinase 3 (FLT3) inhibitors for both low‐intensity and high‐intensity regimens in FLT3‐mutated acute myeloid leukemia
  di: Pamela S. Becker
  Pubblicazione: (2025)
• Optimizing treatment selection and timing of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia with concurrent feline McDonough sarcoma (FMS)‐like tyrosine kinase 3 internal tandem duplication, nucleophosmin 1 and deoxyribonucleic acid (DNA) methyltransferase 3 alpha mutations
  di: Ruixin Li, et al.
  Pubblicazione: (2026)
• Outcomes of pregnancy in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors
  di: Takeshi Kondo, et al.
  Pubblicazione: (2024)
• How receptor tyrosine kinase‐like orphan receptor 1 meets its partners in chronic lymphocytic leukemia
  di: Nayla Mouawad, et al.
  Pubblicazione: (2024)